Description
This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.
Faculty
- Thomas Berg (Moderator)
- Jordan Feld (Faculty)
- Norah Terrault (Faculty)
- Heiner Wedemeyer (Faculty)
This episode is scheduled in honour of the United States’ Viral Hepatitis Awareness Month.
This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no input from GSK or Vir Biotechnology with regards to the content of this programme.
Related episodes
- Season 6, Episode 2: Why do we need HBV functional cure?
- Season 5, Episode 8: JHEP Live: Hepatitis Delta’s Latest Debate: Updates Straight from EASL’s Slate
- Season 5, Episode 3: Zoonotic Hepatitis E: What’s hot in 2023?
- EASL Studio at the EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challenges
- Season 4, Episode 19: HDV: The devil becomes treatable
- Season 4, Episode 1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?
ℹ️ Please click here to access the podcast version of this EASL Studio episode.
